Dovitinib (TKI258) is a small molecule inhibitor of fibroblast growth factor receptor 1 (FGFR1), FGFR2, and FGFR3 that has demonstrated cell growth inhibition in FGFR-amplified breast cancer cell lines and xenograft models (HBCx2) [205]. The gene discussed is FGFR1; the disease is breast carcinoma.